Position in VTGN
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$3,574
-$6,111 QoQ
Shares Held
15,540
-8.5% QoQ
Ownership
0.035%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#33
of 48 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VTGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Truvestments Capital LLC holds $2,305,139 across 79 Biotechnology names. VTGN ranks #45 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
7,833 | $426,193 | |
| 2 | TWST |
Twist Bioscience Corp
|
1,773 | $182,406 | |
| 3 | CRVS |
Corvus Pharmaceuticals, Inc.
|
10,195 | $152,313 | |
| 4 | PTGX |
Protagonist Therapeutics, Inc
|
1,156 | $141,702 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
3,788 | $134,057 | |
| 6 | CTMX |
CytomX Therapeutics, Inc.
|
27,988 | $104,955 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
1,764 | $96,914 | |
| 8 | RIGL |
Rigel Pharmaceuticals Inc
|
2,387 | $93,379 |
All Filings in VTGN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,574 | 15,540 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $9,685 | 16,992 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $11,214 | 16,992 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $30,725 | 8,655 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $14,310 | 7,155 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||